Safety

• 4152 adult and adolescent patients received zanamivir

• Delivered in various dose forms and frequencies

• Similar safety profile to placebo

• Most commonly reported adverse events were consistent with signs and symptoms of influenza-like illness

Previous slide

Next slide

Back to first slide

View graphic version